Egbert F. Smit

59.7k total citations · 13 hit papers
692 papers, 29.3k citations indexed

About

Egbert F. Smit is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Egbert F. Smit has authored 692 papers receiving a total of 29.3k indexed citations (citations by other indexed papers that have themselves been cited), including 487 papers in Pulmonary and Respiratory Medicine, 397 papers in Oncology and 127 papers in Molecular Biology. Recurrent topics in Egbert F. Smit's work include Lung Cancer Treatments and Mutations (415 papers), Lung Cancer Research Studies (185 papers) and Lung Cancer Diagnosis and Treatment (170 papers). Egbert F. Smit is often cited by papers focused on Lung Cancer Treatments and Mutations (415 papers), Lung Cancer Research Studies (185 papers) and Lung Cancer Diagnosis and Treatment (170 papers). Egbert F. Smit collaborates with scholars based in Netherlands, United States and Germany. Egbert F. Smit's co-authors include Pieter E. Postmus, Harry J.M. Groen, Giuseppe Giaccone, David Planchard, Otto S. Hoekstra, Suresh Senan, Solange Peters, Erik Thunnissen, Tony Mok and Keith M. Kerr and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Egbert F. Smit

671 papers receiving 28.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 2.4k citations Masahiro Fukuoka, Seiji Yano et al. Journal of Clinical Oncology profile →
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2018 1.6k citations Silvia Novello, Egbert F. Smit et al. Annals of Oncology profile →
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

2017 948 citations Egbert F. Smit, Harry J.M. Groen et al. profile →
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial

2002 576 citations Harm van Tinteren, Otto S. Hoekstra et al. profile →
Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer

2007 471 citations Jan P. van Meerbeeck, Egbert F. Smit et al. profile →
Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer

2008 439 citations Egbert F. Smit et al. profile →
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

2017 430 citations Myung‐Ju Ahn, Harry J.M. Groen et al. Journal of Clinical Oncology profile →
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

2019 372 citations John B.A.G. Haanen, Egbert F. Smit et al. Annals of Oncology profile →
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 370 citations Lizza Hendriks, Egbert F. Smit et al. Annals of Oncology profile →
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

2016 334 citations Gregory J. Riely, Egbert F. Smit et al. profile →
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 286 citations Lizza Hendriks, Egbert F. Smit et al. Annals of Oncology profile →
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

2022 121 citations Egbert F. Smit, D. Ross Camidge et al. profile →
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

2024 76 citations Egbert F. Smit, Enriqueta Felip et al. profile →

Peers

Countries citing papers authored by Egbert F. Smit

Since Specialization

Citations

This map shows the geographic impact of Egbert F. Smit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Egbert F. Smit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Egbert F. Smit more than expected).

Fields of papers citing papers by Egbert F. Smit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Egbert F. Smit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Egbert F. Smit. The network helps show where Egbert F. Smit may publish in the future.

Co-authorship network of co-authors of Egbert F. Smit

This figure shows the co-authorship network connecting the top 25 collaborators of Egbert F. Smit. A scholar is included among the top collaborators of Egbert F. Smit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Egbert F. Smit. Egbert F. Smit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy 2024 ·Frontiers in Immunology ·Anastasia Gangaev, Yannick van Sleen, (unknown), (unknown), (unknown), (unknown), Annemarie Boerma, Marieke van der Heiden, Sjoukje F. Oosting, Astrid A.M. van der Veldt, T. Jeroen N. Hiltermann, Corine H. GeurtsvanKessel, Anne‐Marie C. Dingemans, Egbert F. Smit, Elisabeth G.E. de Vries, John B.A.G. Haanen, Pia Kvistborg, Debbie van Baarle	2
2	MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02 2023 ·Journal of Thoracic Oncology ·Pasi A. Jänne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, (unknown), (unknown), Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, (unknown), Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, D.-W. Kim, (unknown), Fang Cheng, Ayumi Taguchi, Yun Cheng, Kōichi Goto	2
3	A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer 2023 ·Cancer ·(unknown), Anthonie J. van der Wekken, Marthe S. Paats, Lizza Hendriks, Sayed M.S. Hashemi, (unknown), Daan van den Broek, Linda J.W. Bosch, Kim Monkhorst, Egbert F. Smit, Adrianus J. de Langen	4
4	1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP) 2023 ·Annals of Oncology ·Karin Verkerk, (unknown), Laurien J. Zeverijn, Birgit S. Geurts, (unknown), (unknown), Paul Roepman, Anne M.L. Jansen, Vincent van der Noort, Egbert F. Smit, Ann Hoeben, Lizza Hendriks, Carla M.L. van Herpen, Berber Piet, (unknown), Sayed M.S. Hashemi, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest, J. De Langen	3
5	1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial 2023 ·Annals of Oncology ·Santiago Viteri, Enriqueta Felip, Frank Griesinger, Marina Chiara Garassino, Hiroshi Sakai, Xiuning Le, Rémi Veillon, Egbert F. Smit, Jo Raskin, Michael Thomas, M-J. Ahn, Soetkin Vlassak, Rolf Bruns, Andreas Johne, Paul K. Paik	3
6	A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors 2020 ·Clinical Cancer Research ·Mirte Muller, Karlijn Hummelink, Daan P. Hurkmans, Anna-Larissa N. Niemeijer, Kim Monkhorst, Joanna Roder, Carlos Oliveira, Heinrich Röder, Joachim G.J.V. Aerts, Egbert F. Smit	17
7	Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study 2020 ·Kölner Universitäts PublikationsServer (Universität zu Köln) ·Jennifer Moriatis Wolf, Tobias R. Overbeck, Ji‐Youn Han, Maximilian J. Hochmair, Filippo de Marinis, Kadoaki Ohashi, Egbert F. Smit, David A. Power, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Maeve Waldron-Lynch, Sylvie Le Mouhaër, (unknown), Marco Giovannini, Rebecca S. Heist	8
8	Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition 2019 ·Molecular Cancer Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), Ida H. van der Meulen‐Muileman, Renée X. de Menezes, (unknown), Kathrin Oehl, Egbert F. Smit, Walter Weder, Rolf A. Stahel, Lorenza Penengo, Victor W. van Beusechem, Emanuela Felley‐Bosco	18
9	Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer 2014 ·Cancer Discovery ·Elza C. de Bruin, Catherine Cowell, Patricia H. Warne, Ming Jiang, Rebecca E. Saunders, Mary Ann Melnick, Scott Gettinger, Zenta Walther, Anna Wurtz, Guus J.J.E. Heynen, Daniëlle A.M. Heideman, Javier Gómez‐Román, Almudena García‐Castaño, Yixuan Gong, Marc Ladanyi, Harold Varmus, René Bernards, Egbert F. Smit, Katerina Politi, Julian Downward	154
10	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations 2014 ·Cancer Discovery ·Yelena Y. Janjigian, Egbert F. Smit, Harry J.M. Groen, Leora Horn, Scott Gettinger, D. Ross Camidge, Gregory J. Riely, Bushi Wang, Yali Fu, Vikram K. Chand, Vincent A. Miller, William Pao	295
11	Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis 2014 ·Journal of Clinical Pathology ·Annemarie Hübers, Paul Brinkman, (unknown), (unknown), Birgit I. Lissenberg‐Witte, Aeilko H. Zwinderman, Daniëlle A.M. Heideman, Sylvia Duin, (unknown), Renske D.M. Steenbergen, Peter J.F. Snijders, Egbert F. Smit, Peter J. Sterk, Erik Thunnissen	59
12	Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography 2013 ·Clinical Cancer Research ·Astrid A.M. van der Veldt, Mark Lubberink, Ron H.J. Mathijssen, Walter J. Loos, Gerarda J.M. Herder, Henri N. Greuter, Emile F.I. Comans, (unknown), Jonas Eriksson, Albert D. Windhorst, N. Harry Hendrikse, Pieter E. Postmus, Egbert F. Smit, Adriaan A. Lammertsma	60
13	Power of the past: a randomized controlled trial to assess effectiveness of life review therapy in palliative cancer patients 2013 ·University of Twente Research Information ·Gitta Kleijn, (unknown), Annemarie Becker‐Commissaris, (unknown), (unknown), (unknown), (unknown), (unknown), Egbert F. Smit, (unknown), Bas Steunenberg, Ernst T. Bohlmeijer, (unknown), (unknown)	2
14	Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status 2012 ·Clinical Cancer Research ·Idris Bahce, Egbert F. Smit, Mark Lubberink, Astrid A.M. van der Veldt, Maqsood Yaqub, Albert D. Windhorst, Robert C. Schuit, Erik Thunnissen, Daniëlle A.M. Heideman, Pieter E. Postmus, Adriaan A. Lammertsma, N. Harry Hendrikse	92
15	An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer 2008 ·Clinical Cancer Research ·Paul Roepman, Jacek Jassem, Egbert F. Smit, Thomas Muley, Jacek Nikliński, Tony van de Velde, Anke Witteveen, Witold Rzyman, Arno Floore, Sjaak A. Burgers, Giuseppe Giaccone, Michael Meister, Hendrik Dienemann, Marcin Skrzypski, Mirosław Kozłowski, Wolter J. Mooi, Nico van Zandwijk	114
16	Traditional Versus Up-Front [ ¹⁸ F] Fluorodeoxyglucose–Positron Emission Tomography Staging of Non–Small-Cell Lung Cancer: A Dutch Cooperative Randomized Study 2006 ·Journal of Clinical Oncology ·Gerarda J.M. Herder, Henk Kramer, Otto S. Hoekstra, Egbert F. Smit, Jan Pruim, Harm van Tinteren, Emile F.I. Comans, Paul Verboom, Carin A. Uyl‐de Groot, (unknown), Marinus A. Paul, Maarten Boers, Pieter E. Postmus, G. J. J. Teule, Harry J.M. Groen	108
17	Non-small cell lung cancer and health-related quality of life (HRQOL): Is baseline HRQOL of prognostic value for survival? 2005 ·Open Repository and Bibliography (University of Liège) ·Andrew Bottomley, Egbert F. Smit, Fabio Efficace, (unknown), Hans J.M. Smit, Rabab Gaafar, Bonne Biesma, P. Lianes, Kristel Van Steen, Corneel Coens, Jan P. van Meerbeeck	1
18	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer breakdown → 2003 ·Journal of Clinical Oncology ·Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean‐Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert F. Smit, Steven D. Averbuch, (unknown), A. Feyereislova, (unknown), José Baselga	2392
19	Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin‐resistant tumor cell lines 1997 ·International Journal of Cancer ·Marleen Bakker, Johan Renes, (unknown), P. Visser, Hetty Timmer‐Bosscha, Michael Müller, Harry J.M. Groen, Egbert F. Smit, Elisabeth G.E. de Vries	4
20	Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines 1997 ·International Journal of Cancer ·(unknown), Johan Renes, (unknown), P. Visser, Hetty Timmer‐Bosscha, Michael Müller, Harry J.M. Groen, Egbert F. Smit, Elisabeth G.E. de Vries	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact